Stockreport

Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis

IPSEN SA S/ADR  (IPSEY) 
NASDAQ:AMEX Investor Relations: ipsen.com/investors
PDF Trial investigating Cabometyx® (cabozantinib) in combination with atezolizumab demonstrated a positive trend towards improvement for one of the primary endpoints of over [Read more]